Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
Telix Pharmaceuticals announced an upcoming educational webinar highlighting advancements in PSMA-targeted radionuclide therapy, featuring data from the OPTIMAL-PSMA2 trial of their novel candidate TLX597-Tx. The webinar aims to discuss the potential of Telix's differentiated multi-product approach to treating prostate cancer and facilitate patient…